D.E. Shaw & Co’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-388,986
| Closed | -$40.4M | – | 4358 |
|
|
2025
Q1 | $34.4M | Buy |
388,986
+27,185
| +8% | +$2.65M | 0.03% | 642 |
|
|
2024
Q4 | $31.6M | Buy |
361,801
+106,111
| +41% | +$9.72M | 0.02% | 784 |
|
|
2024
Q3 | $23.7M | Sell |
255,690
-46,945
| -16% | -$4.66M | 0.02% | 901 |
|
|
2024
Q2 | $32.6M | Sell |
302,635
-73,542
| -20% | -$7.36M | 0.03% | 632 |
|
|
2024
Q1 | $35.7M | Buy |
376,177
+26,860
| +8% | +$2.3M | 0.03% | 615 |
|
|
2023
Q4 | $32.2M | Buy |
349,317
+335,279
| +2,388% | +$21.7M | 0.03% | 653 |
|
|
2023
Q3 | $705K | Buy |
+14,038
| New | +$750K | ﹤0.01% | 3276 |
|
|
2023
Q2 | – | Sell |
-21,270
| Closed | -$957K | – | 4253 |
|
|
2023
Q1 | $957K | Sell |
21,270
-18,086
| -46% | -$815K | ﹤0.01% | 3196 |
|
|
2022
Q4 | $1.72M | Buy |
39,356
+7,807
| +25% | +$374K | ﹤0.01% | 3047 |
|
|
2022
Q3 | $2.08M | Sell |
31,549
-6,298
| -17% | -$405K | ﹤0.01% | 2970 |
|
|
2022
Q2 | $1.91M | Sell |
37,847
-13,522
| -26% | -$792K | ﹤0.01% | 3113 |
|
|
2022
Q1 | $3.28M | Sell |
51,369
-128,398
| -71% | -$9.22M | ﹤0.01% | 2790 |
|
|
2021
Q4 | $19.3M | Sell |
179,767
-27,382
| -13% | -$2.86M | 0.02% | 1118 |
|
|
2021
Q3 | $21.3M | Sell |
207,149
-63,948
| -24% | -$5.96M | 0.02% | 982 |
|
|
2021
Q2 | $23.8M | Buy |
271,097
+13,355
| +5% | +$1.22M | 0.02% | 926 |
|
|
2021
Q1 | $25.1M | Sell |
257,742
-19,892
| -7% | -$1.99M | 0.02% | 810 |
|
|
2020
Q4 | $31.1M | Sell |
277,634
-23,454
| -8% | -$2.47M | 0.03% | 731 |
|
|
2020
Q3 | $27.9M | Buy |
301,088
+262,769
| +686% | +$20.2M | 0.03% | 665 |
|
|
2020
Q2 | $2.99M | Sell |
38,319
-106,462
| -74% | -$7.2M | ﹤0.01% | 2085 |
|
|
2020
Q1 | $8.47M | Sell |
144,781
-13,489
| -9% | -$868K | 0.01% | 1088 |
|
|
2019
Q4 | $12.7M | Buy |
158,270
+47,339
| +43% | +$3.54M | 0.01% | 1057 |
|
|
2019
Q3 | $8.15M | Sell |
110,931
-128,502
| -54% | -$11.1M | 0.01% | 1304 |
|
|
2019
Q2 | $22.6M | Buy |
239,433
+150,365
| +169% | +$12.4M | 0.03% | 688 |
|
|
2019
Q1 | $7.13M | Buy |
+89,068
| New | +$6.58M | 0.01% | 1317 |
|
|
2018
Q2 | – | Sell |
-27,613
| Closed | -$2.53M | – | 3701 |
|
|
2018
Q1 | $2.53M | Buy |
+27,613
| New | +$2.38M | ﹤0.01% | 1882 |
|
|
2017
Q1 | – | Sell |
-38,097
| Closed | -$1.07M | – | 3302 |
|
|
2016
Q4 | $1.07M | Buy |
38,097
+14,942
| +65% | +$450K | ﹤0.01% | 2416 |
|
|
2016
Q3 | $688K | Buy |
+23,155
| New | +$575K | ﹤0.01% | 2622 |
|
|
2015
Q3 | – | Sell |
-34,191
| Closed | -$906K | – | 3724 |
|
|
2015
Q2 | $906K | Buy |
+34,191
| New | +$976K | ﹤0.01% | 2779 |
|
Other funds holding BPMC
IA
HNB
D.E. Shaw & Co's BPMC Position: Q2 2025 in Review
D.E. Shaw & Co sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 388,986 shares — an estimated $40.4M sold.
D.E. Shaw & Co first reported a position in BPMC in Q2 2015 and held it in 28 quarters. The position peaked at $35.7M in Q1 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.
- D.E. Shaw & Co reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 388,986 Blueprint Medicines shares in Q2 2025, an estimated $40.4M.
- D.E. Shaw & Co first reported a position in Blueprint Medicines in Q2 2015 and held it in 28 quarters.
- D.E. Shaw & Co's Blueprint Medicines position peaked at $35.7M in Q1 2024.
- 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.
Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.